Hetero launches the biosimilar ‘Adalimumab’ under the brand name ‘Mabura’ in India
India, Hyderabad, 3rd January 2018: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, today announces the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘MaburaTM’ in India. The product will be marketed and distributed by Hetero Healthcare in the country.
MaburaTM is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis etc. MaburaTM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously.
Hetero’s MaburaTM is the Biosimilar version of AbbVie’s HumiraTM. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.
The product will be manufactured at our dedicated state-of-the-art manufacturing facility for Biologics, based at Hyderabad, India.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 20 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars and custom pharmaceutical services. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.
Hetero has 33 state-of-the-art manufacturing facilities strategically located worldwide. And a majority of our facilities have been successfully audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.
Hetero has a strong global presence in over 120 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com